Learn · Topic guide

Peptide Classes Explained

Peptides are short chains of amino acids, and in laboratory research they are rarely studied as an undifferentiated group. Investigators sort them by what they do at the molecular level: which receptor they bind, which intracellular cascade they trigger, or which biochemical process they modulate in a cell-free or cultured-cell system. This reference organizes a set of research peptides by functional class rather than by chemical size or origin. The groupings used here are growth hormone secretagogues, incretin-receptor agonists, regenerative and matrix-signaling peptides, nootropic neuropeptides, cosmetic matricellular peptides, and mitochondrial-derived peptides. Each class is defined by a shared mechanistic signature observed in receptor-binding assays, second-messenger readouts, or gene-expression profiling. Every peptide-specific statement below is drawn from a curated dataset of in-vitro and structural findings, and the framing is strictly that of laboratory research: receptor occupancy, signal transduction, and biochemical activity. No human dosing, clinical outcome, or disease-treatment interpretation is offered. The goal is a clear conceptual map of how research peptides differ in molecular target and signaling logic.

Research use onlyStart reading ↓

Key takeaways

Research peptides are most usefully grouped by molecular function (receptor target and signaling cascade) rather than by amino-acid count or origin.
Growth hormone secretagogues split into two receptor routes: GHRHR agonists (sermorelin, tesamorelin, CJC-1295) signaling via Gs/cAMP/PKA, and GHS-R1a/ghrelin-receptor agonists (GHRP-2) signaling via Gq/11/PLC/calcium.
Incretin-class peptides target class B1 Gs-coupled GPCRs; semaglutide is a GLP-1R full agonist, while retatrutide is a single peptide agonizing GIPR, GLP-1R, and GCGR simultaneously.
Regenerative and matrix-signaling peptides (BPC-157, TB-500, KPV) act largely without a single cloned receptor, modulating angiogenic signaling, actin dynamics, or inflammatory cascades in cell models.
GHK-Cu (cosmetic/matricellular) and MOTS-c (mitochondrial-derived) define narrow classes built on copper-coordination collagen-gene signaling and AMPK/NRF2 activation, respectively.
Recurring engineering motifs across classes include DPP-4/DPP-IV resistance (D-Ala2, Aib, N-terminal acylation) and fatty-acid or albumin binding to extend in-vitro molecular residence.

Section 01

Why Classify Peptides by Function

A peptide's amino-acid count tells you little about its biology.

A peptide's amino-acid count tells you little about its biology. A 15-residue cytoprotective peptide and a 16-residue mitochondrial microprotein share a length range but act through entirely unrelated mechanisms. Functional classification instead groups peptides by their molecular target and the signaling cascade they engage in laboratory models. This is the framework that structural and pharmacology papers actually use. One axis is receptor identity: many research peptides are agonists at G-protein-coupled receptors (GPCRs), and the receptor class largely predicts the downstream second messenger. Class B GPCRs such as the GHRH receptor and the GLP-1 receptor couple to the stimulatory G-protein Gs, activating adenylyl cyclase and raising intracellular cAMP. Other peptides bypass classical receptors entirely and act biochemically, for instance by sequestering monomeric actin or by binding DNA. A second axis is the biological process modulated, such as extracellular-matrix remodeling, neurotrophin expression, or energy-sensing kinase activation. Sorting peptides this way clarifies why two molecules with similar structures behave differently and why structurally distinct peptides can converge on the same pathway. The classes below follow this logic, each anchored to a defining in-vitro signaling readout rather than to marketing categories.

Section 02

Growth Hormone Secretagogues: Two Receptor Routes

Growth hormone secretagogues (GHS) are research peptides that engage the somatotroph signaling machinery of the pituitary in cell and tissue models.

Growth hormone secretagogues (GHS) are research peptides that engage the somatotroph signaling machinery of the pituitary in cell and tissue models. The dataset shows two distinct receptor routes. The first is the GHRH-receptor (GHRHR) class, a Group B Gs-coupled GPCR. Sermorelin is the native human GHRH(1-29) fragment and the shortest sequence retaining full GHRH activity; tesamorelin is the full GHRH(1-44) backbone carrying a trans-3-hexenoyl group on Tyr1; and CJC-1295 (both the no-DAC Mod GRF 1-29 form and the DAC form) is a tetrasubstituted GRF(1-29) amide with D-Ala2, Gln8, Ala15, and Leu27 substitutions. All four couple GHRHR to Gs, activating adenylyl cyclase and raising cAMP, which engages PKA and CREB-mediated transcription in somatotroph models. The second route is the ghrelin receptor (GHS-R1a), a class A GPCR. GHRP-2, a synthetic hexapeptide, is a GHS-R1a agonist that signals predominantly through Gq/11, phospholipase C, IP3/DAG, intracellular calcium, and protein kinase C. The structural theme uniting the GHRH analogs is resistance to DPP-IV cleavage, conferred by D-Ala2 substitution or N-terminal acylation, with the DAC variant adding covalent albumin binding via a maleimide-Cys34 thioether.

Section 03

Incretin-Receptor Agonists

Incretin-class research peptides are agonists at the receptors for the gut hormones GLP-1 and GIP, plus the related glucagon receptor.

Incretin-class research peptides are agonists at the receptors for the gut hormones GLP-1 and GIP, plus the related glucagon receptor. All three are class B1 Gs-coupled GPCRs, so the standard in-vitro readout is cAMP accumulation in receptor-expressing cells. Semaglutide is a 31-residue analog of human GLP-1(7-37), roughly 94% homologous, acting as a full agonist at the GLP-1 receptor with a reported recombinant binding affinity near 0.38 nM. Cryo-EM of the semaglutide-GLP-1R-Gs complex shows canonical Gs coupling with a characteristic kink in transmembrane helix 6, and downstream signaling involves PKA, Epac2, and beta-arrestin recruitment. Retatrutide is structurally more ambitious: a single 39-residue peptide that is a balanced agonist at three receptors at once (GIPR, GLP-1R, and GCGR), with comparatively greater GIPR activity in cAMP assays. Cryo-EM of its receptor-Gs complexes reveals a conserved N-terminal insertion into the orthosteric pocket, while mid-region sequence variation is read out by receptor-specific extracellular-loop contacts, rationalizing simultaneous tri-receptor activation. Both peptides share engineering motifs: alpha-aminoisobutyric-acid (Aib) substitutions for DPP-4 resistance and helix stabilization, plus fatty-diacid acylation that drives reversible albumin binding to extend molecular residence in vitro.

Section 04

Regenerative and Matrix-Signaling Peptides

BPC-157 is a synthetic 15-amino-acid peptide representing a partial sequence of a human gastric-juice protein.

This class groups peptides whose characterized in-vitro activity centers on cytoprotection, cytoskeletal regulation, and extracellular-matrix or inflammatory signaling, often without acting through a single cloned receptor. BPC-157 is a synthetic 15-amino-acid peptide representing a partial sequence of a human gastric-juice protein. In endothelial-cell models it up-regulates VEGFR2 expression and promotes its internalization, driving the dynasore-sensitive VEGFR2-Akt-eNOS cascade, and it engages a VEGF-independent Src-Caveolin-1-eNOS route; in tendon fibroblasts it increases FAK and paxillin phosphorylation and promotes F-actin assembly and migration. TB-500 is the N-acetylated heptapeptide Ac-LKKTETQ, corresponding to residues 17-23 of thymosin beta-4 and containing the conserved LKKTET actin-binding motif; its parent acts as the principal intracellular G-actin-sequestering peptide, buffering the monomeric actin pool in cell-free systems. KPV, the C-terminal tripeptide of alpha-MSH, is taken up via the PepT1 transporter in cultured intestinal epithelium and attenuates cytokine-stimulated NF-kB and MAP-kinase signaling at nanomolar concentrations in a largely receptor-independent manner. The unifying thread is modulation of repair-associated cellular processes rather than classical GPCR agonism.

Section 05

Cosmetic and Mitochondrial Classes

Two narrower functional classes round out the picture.

Two narrower functional classes round out the picture. The cosmetic, or matricellular, class is represented by GHK-Cu, the 1:1 coordination complex of the tripeptide glycyl-L-histidyl-L-lysine with Cu(II). The copper ion is coordinated by the histidine imidazole nitrogen, the glycine alpha-amino nitrogen, and the deprotonated Gly-His amide nitrogen. In cultured dermal fibroblasts the complex stimulates collagen type I/III gene and protein expression maximally near nanomolar concentrations, and it coordinately modulates MMP-2 alongside its tissue inhibitors TIMP-1 and TIMP-2, an MMP-2 effect attributed to the copper moiety. Transcriptomic profiling indicates broad gene-expression modulation across matrix-remodeling, antioxidant, and DNA-repair pathway sets. The mitochondrial-derived peptide (MDP) class is represented by MOTS-c, a 16-residue microprotein encoded by a short open reading frame within the mitochondrial 12S rRNA (MT-RNR1) gene. In cultured cells it modulates the folate-methionine one-carbon cycle, promoting AICAR accumulation that allosterically activates AMPK by a route largely independent of the AMP:ATP ratio. Under metabolic stress it translocates to the nucleus in an AMPK-dependent manner and associates with NRF2 at antioxidant-response elements, an example of mitonuclear transcriptional crosstalk.

Section 06

Nootropic and Other Receptor-Defined Peptides

The nootropic class is defined by modulation of neurotrophin signaling in neural-tissue models.

The nootropic class is defined by modulation of neurotrophin signaling in neural-tissue models. Semax is a synthetic heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro, combining the ACTH(4-7) fragment with a C-terminal Pro-Gly-Pro tail that shields it from aminopeptidase cleavage. In rat basal-forebrain membrane binding assays it shows specific, reversible binding with a dissociation constant of 2.4 +/- 1.0 nM. Ex-vivo and cell models report up-regulation of BDNF protein and exon-specific BDNF mRNA together with increased TrkB tyrosine phosphorylation, implicating downstream neurotrophin-receptor cascades such as MAPK/ERK and PI3K/Akt; lacking the corticotropic N-terminal ACTH residues, it is described as devoid of classical adrenal-stimulating activity. Two further melanocortin-family peptides illustrate how receptor identity drives classification. Bremelanotide (PT-141) is a cyclic heptapeptide alpha-MSH analog acting as a non-selective melanocortin-receptor agonist (MC1R/MC3R/MC4R), producing concentration-dependent cAMP accumulation in MC4R-expressing HEK-293 cells. Epitalon, a linear tetrapeptide (Ala-Glu-Asp-Gly), differs sharply: it lacks a defined membrane receptor and instead penetrates the nucleus, binds DNA sequence-specifically, and in cultured human cells is reported to induce hTERT expression and telomerase activity, framing it within gerontology and epigenetic gene-expression research.

Straight answers

Frequently asked questions

What does it mean to classify a peptide by function?

Functional classification groups research peptides by their molecular target and the intracellular cascade they engage in laboratory models, rather than by size or chemical family. For example, GHRH-receptor agonists are grouped because they all couple a class B GPCR to Gs, raising cAMP, while a mitochondrial-derived peptide like MOTS-c is grouped separately because it modulates the folate one-carbon cycle and activates AMPK. The shared mechanistic signature, observed in binding assays or second-messenger readouts, defines the class.

How do GHRH-receptor secretagogues differ from ghrelin-receptor secretagogues?

In the dataset, both engage pituitary somatotroph signaling but through different receptors and second messengers. GHRHR agonists (sermorelin, tesamorelin, CJC-1295) bind a class B Gs-coupled GPCR and signal via adenylyl cyclase, cAMP, PKA, and CREB. GHRP-2 binds GHS-R1a (the ghrelin receptor), a class A GPCR that signals predominantly through Gq/11, phospholipase C, IP3/DAG, intracellular calcium, and protein kinase C. The two routes are distinct receptor-signaling mechanisms.

What makes retatrutide different from semaglutide in the incretin class?

Both target class B1 Gs-coupled incretin receptors with cAMP accumulation as the in-vitro readout. Semaglutide is a single-receptor full agonist at GLP-1R, a 31-residue GLP-1(7-37) analog. Retatrutide is a unimolecular triple agonist that engages GIPR, GLP-1R, and GCGR simultaneously, with comparatively greater GIPR activity in cAMP assays. Cryo-EM studies attribute its tri-receptor activity to a conserved N-terminal insertion plus receptor-specific extracellular-loop contacts.

Why are BPC-157 and TB-500 grouped as regenerative rather than receptor-defined?

Both are characterized in vitro by activity that does not map onto a single cloned receptor. BPC-157 modulates endothelial and fibroblast signaling, up-regulating VEGFR2 expression and engaging the VEGFR2-Akt-eNOS and Src-Caveolin-1-eNOS pathways. TB-500 (Ac-LKKTETQ) derives from thymosin beta-4 and its parent acts biochemically as a G-actin-sequestering peptide. Their classification rests on the cellular process modulated, repair-associated signaling and cytoskeletal dynamics, rather than on a defining receptor.

What is a mitochondrial-derived peptide?

A mitochondrial-derived peptide (MDP) is a bioactive microprotein encoded by a short open reading frame within mitochondrial DNA. The dataset example is MOTS-c, a 16-residue peptide encoded within the mitochondrial 12S rRNA (MT-RNR1) gene. In cultured cells it modulates the folate-methionine one-carbon cycle, promoting AICAR accumulation that activates AMPK by an energy-charge-independent route, and under metabolic stress it translocates to the nucleus and associates with NRF2 at antioxidant-response elements.

Do all the peptides in these classes act through receptors?

No. Several act biochemically rather than through a membrane receptor. TB-500's parent sequesters monomeric actin in cell-free systems; GHK-Cu functions as a copper-coordination complex that modulates collagen-gene expression in fibroblasts; and Epitalon is a tetrapeptide reported to enter the nucleus and bind DNA sequence-specifically, with no defined membrane receptor characterized. These illustrate that functional classification spans both receptor-mediated and receptor-independent mechanisms observed in laboratory models.

Keep exploring

Continue learning

Topic guideWhat Are Research Peptides?Research peptides are short chains of amino acids studied in the laboratory to understand how cells receive, interpret, and relay molecular signals. Because peptides sit at the size boundary between simple amino acids and large folded proteins, they make precise tools for asking narrow biochemical questions: which receptor does a given sequence engage, what second messenger rises inside the cell, and how does a small change to the chain alter that behavior? This reference looks at what defines a peptide, how peptides differ from proteins, what the label "research use only" (RUO) means, and why these molecules are examined in cell-based and cell-free systems rather than treated as finished products. Throughout, the framing is strictly in-vitro and receptor-signaling: the discussion concerns binding assays, cultured cells, isolated tissues, and structure-activity studies. Specific peptide facts cited here are drawn from a curated reference dataset of characterized research peptides. General principles of peptide chemistry are presented as established background. Nothing here describes administration, outcomes, or use in people; the goal is conceptual literacy for laboratory and educational contexts.Read →Topic guideGrowth Hormone Secretagogues ExplainedGrowth hormone secretagogues (GHS) are a research category defined by mechanism rather than chemistry: each is a molecule that, in laboratory and cell-based systems, prompts pituitary somatotroph cells to release stored growth hormone instead of supplying growth hormone from outside the system. The category splits cleanly into two receptor branches. One branch acts at the growth hormone-releasing hormone receptor (GHRH-R); the other acts at the growth hormone secretagogue receptor type 1a (GHS-R1a), the receptor for endogenous ghrelin. These two receptors sit on the same cells but run through different G-protein cascades, which is why the distinction matters at the bench. This reference article explains GHS-R1a signaling, contrasts GHRH analogs with ghrelin-mimetic growth hormone-releasing peptides (GHRPs), describes why GH release is pulsatile, and clarifies the conceptual line between a secretagogue and an exogenous hormone. All statements here are framed strictly around in-vitro and receptor-signaling observations in research models. Peptide-specific facts are drawn only from a controlled reference dataset; broader statements are presented as general principles of peptide endocrinology, not as claims about any outcome.Read →Topic guideGHRH Analogs vs GHRPsTwo families of research peptides frequently appear together in growth-hormone-axis signaling studies: growth-hormone-releasing hormone (GHRH) analogs and growth-hormone-releasing peptides (GHRPs). Although both are described in the literature as growth hormone secretagogues, they engage entirely different cell-surface receptors and trigger different intracellular second-messenger cascades in laboratory models. GHRH analogs such as sermorelin and CJC-1295 act at the GHRH receptor (GHRHR), a class B Gs-coupled G-protein-coupled receptor on pituitary somatotroph cells. GHRPs such as GHRP-2 act at the growth hormone secretagogue receptor type 1a (GHS-R1a) - the ghrelin receptor - a class A GPCR coupled to a separate signaling arm. This article compares the two receptor systems as characterized in in-vitro and ex-vivo work, explains why their pathways are described as complementary, and grounds each peptide-specific claim in the reference dataset. The framing throughout is strictly receptor-signaling and laboratory-research: cAMP and calcium readouts in cultured cells, binding constants, and structure-activity relationships, not clinical outcomes. Understanding the receptor-level distinction clarifies why these two peptide classes are studied as separate but convergent inputs onto the somatotroph.Read →Topic guideGLP-1 / Incretin Agonists ExplainedThe incretin system is one of the most studied signaling axes in modern receptor pharmacology, and the peptides that engage it have become reference tools for probing class B G-protein-coupled receptor (GPCR) biology in vitro. "Incretin" describes gut-derived peptides that amplify cellular signaling in response to nutrient cues, acting through a small family of related receptors. This reference article surveys the molecular logic of those receptors, GLP-1R, GIPR, and the glucagon receptor (GCGR), and explains how synthetic peptide agonists are classified by the number of receptors they engage: mono-agonists, dual agonists, and triple agonists. Where specific peptides are named, the discussion draws only on laboratory-characterized data: semaglutide as a GLP-1R mono-agonist and retatrutide as a unimolecular GIPR/GLP-1R/GCGR triple agonist. Throughout, the framing is strictly biochemical and structural, describing receptor binding, cyclic AMP (cAMP) accumulation in recombinant cells, and the engineering features that govern molecular stability in assay systems. No clinical, dosing, or therapeutic interpretation is offered or implied; the content is intended for laboratory-research and receptor-signaling education only.Read →

For in-vitro laboratory research use only. Not for human or animal consumption. Educational content, not medical advice; not intended to diagnose, treat, cure, or prevent any disease. Not evaluated by the FDA.